









Markets
/
Stocks
/
nasdaq-lgvn
/

Longeveron Inc

LGVN

0.929USD

-0.044-4.51%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

1.74MMarket Cap

LossP/E TTM



Longeveron Inc

0.929

-0.044-4.51%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Longeveron Inc

Currency: USD Updated: 2026-03-27

Key Insights

Longeveron Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 146 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.61.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Longeveron Inc's Score

Industry at a Glance

Industry Ranking

146 / 391

Overall Ranking

270 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Longeveron Inc Highlights

StrengthsRisks

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 69.11% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.20M.

Fairly Valued

The company’s latest PE is -0.71, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.71M shares, increasing 26.72% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 499.13K shares of this stock.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

6.612

Target Price

+579.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Longeveron Inc is 6.03, ranking 297 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 365.00K, representing a year-over-year decrease of 39.47%, while its net profit experienced a year-over-year decrease of 33.40%.

Score

Industry at a Glance

Previous score

6.03

Change



Financials

7.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.12

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Longeveron Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Longeveron Inc is 8.53, ranking 40 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.71, which is -1063.11% below the recent high of 6.86 and -581.55% above the recent low of -4.85.

Score

Industry at a Glance

Previous score

8.53

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Longeveron Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 10.45 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

6.612

Target Price

+618.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Longeveron Inc

LGVN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Longeveron Inc is 5.23, ranking 323 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.27 and the support level at 0.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.31

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.004

Buy

RSI(14)

57.746

Neutral

STOCH(KDJ)(9,3,3)

35.779

Neutral

ATR(14)

0.192

Low Volatility

CCI(14)

-21.496

Neutral

Williams %R

47.832

Neutral

TRIX(12,20)

2.620

Buy

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

0.943

Sell

MA10

0.963

Sell

MA20

0.812

Buy

MA50

0.658

Buy

MA100

0.640

Buy

MA200

0.850

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Longeveron Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 8.62%, representing a quarter-over-quarter decrease of 0.99%. The largest institutional shareholder is The Vanguard, holding a total of 499.13K shares, representing 1.80% of shares outstanding, with 67.69% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

676.23K

The Vanguard Group, Inc.

Star Investors

505.57K

+250.43%

Lehr (Paul T)

325.36K

-1.50%

Hashad (Mohamed Wa'el Ahmed)

310.90K

+115.83%

Hare (Joshua M)

253.07K

-2.03%

Soffer (Rock J)

179.52K

+10.46%

Locklear (Lisa)

152.42K

-7.23%

Geode Capital Management, L.L.C.

141.50K

Agafonova (Nataliya)

140.15K

-7.82%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Longeveron Inc is 2.54, ranking 217 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -0.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.